- Pivotal Phase 3 study evaluating atogepant in adult patients with chronic migraine meets primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo across the 12-week treatment period¹
- Study also demonstrates statistically significant improvements in all secondary endpoints¹
- Overall safety profile is consistent with safety findings observed in previous studies with an episodic migraine population¹
- Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
- These results strengthen AbbVie's commitment to advancing its portfolio of medicines to help more people living with migraine
PR Newswire
NORTH CHICAGO, Ill., March 10, 2022